Physician profile
Ahmad M Fahmy
NPI 1598750929
$221,786.35
in general payments reported to CMS, 2019-2025
19 companies · $69K in 2025
The $69K reported for 2025 was more than what 99% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $19K · 2021: $21K · 2022: $43K · 2023: $27K · 2024: $16K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Consulting Fee: $29K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $25K · Travel and Lodging: $16K · Food and Beverage: $2,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,376.20 |
| Consulting Fee | $29,277.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $25,200.00 |
| Travel and Lodging | $16,015.02 |
| Food and Beverage | $2,968.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $41,565.13 | 2019-2025 | |
| Allergan, INC. | $33,218.92 | 2019-2022 | |
| Sight Sciences, INC. | $27,946.38 | 2019-2025 | Tearcare System, Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $27,483.28 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $21,946.85 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $16,104.73 | 2019-2025 | |
| Abbvie INC. | $15,038.49 | 2022-2025 | |
| Biotissue Holdings INC. | $14,692.13 | 2019-2025 | |
| Alcon Vision LLC | $10,725.22 | 2021-2025 | Tryptyr |
| Bausch & Lomb Americas INC. | $5,450.87 | 2025 | Miebo, Xiidra |
| Alcon Research LLC | $3,150.00 | 2024-2025 | Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $1,750.00 | 2019 | |
| Kala Pharmaceuticals, INC. | $1,053.93 | 2021 | |
| Horizon Therapeutics Plc | $1,025.01 | 2019-2021 | |
| Ocular Therapeutix, INC. | $412.07 | 2019-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $208.85 | 2021-2022 | |
| Shire North American Group INC | $14.49 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Fahmy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.